Clinical efficacy and recovery levels of recombinant FVIIa (NovoSeven) in the treatment of intracranial haemorrhage in severe neonatal FVII deficiency.
The use of replacement FVII is critical to the successful treatment of life-threatening bleeds in newborns and infants with severe FVII deficiency (<1%). However, the clinical efficacy, optimum dosage and pharmacologic recovery of rFVIIa in such children has not been studied systematically. This report is a case of an infant with severe FVII deficiency (FVII:C at 0%) and massive intracranial haemorrhage in which successful use of rFVIIa (NovoSeven) was carefully monitored. The drug was administered by intravenous bolus through a central line every 4 h at each of three dose levels: 15 microg kg-1, 22 microg kg-1 and 30 microg kg-1. FVII:C was >100% between 30 and 180 min after each infusion with mean trough levels above 25% for all three dose levels. There was no evidence of hyper-coagulation as indicated by measurements of the platelet count, D-dimer, plasma protamine paracoagulant and fibrinogen levels in spite of high FVII:C concentration. In this infant, rFVIIa was well-tolerated, maintained effective haemostasis with good clinical outcome, and produced consistent therapeutic mean trough levels above 25% FVII:C even at 15 microg kg-1 every 4 h.
Wong
W Y
WY
Division of Hematology-Oncology, Childrens Hospital of Los Angeles, Los Angeles, California 90027-6016, USA.
Huang
W C
WC
Miller
R
R
McGinty
K
K
Whisnant
J K
JK
D000941:Antigens / Q000097:blood / Q000378:metabolism; D001780:Blood Coagulation Tests; D005167:Factor VII / Q000378:metabolism; D005168:Factor VII Deficiency / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D015942:Factor VIIa / Q000009:adverse effects / Q000627:therapeutic use*; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D006406:Hematoma / Q000209:etiology; D006487:Hemostasis; D006630:Hispanic or Latino / Q000235:genetics; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000097:blood / Q000188:drug therapy*; D020300:Intracranial Hemorrhages / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008297:Male; D010976:Platelet Count; D011479:Protamines / Q000097:blood; D011516:Prothrombin / Q000378:metabolism; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D014812:Vitamin K / Q000008:administration & dosage
D000941:Antigens; D005338:Fibrin Fibrinogen Degradation Products; D011479:Protamines; D011994:Recombinant Proteins; C042580:factor VII clotting antigen; C036309:fibrin fragment D; D014812:Vitamin K; D005167:Factor VII; D011516:Prothrombin; D005340:Fibrinogen; D015942:Factor VIIa